The panel focused on the provisions of the Inflation Reduction Act that aim to lower prescription drug prices under Medicare.
The Inflation Reduction Act is unlikely to generate savings for taxpayers, while disrupting the market and creating perverse ...
Seniors in metro Detroit and across Michigan have an opportunity to sign up for the right Medicare plan during open ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
The Inflation Reduction Act (the Act) of 2022 was controversial at the time the Act was signed into law and remains so. To date, multiple ...
With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
The Biden administration's proposed rule could expand coverage of anti-obesity medications for Medicare and Medicaid ...
The Inflation Reduction Act (IRA) aims to lower prescription drug costs and enhance Medicare benefits. While these changes benefit Medicare recipients, they raise concerns for employer-sponsored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback